Treatment of prostate cancer with Ad5/3Δ24hCG allows non-invasive detection of the magnitude and persistence of virus replication in vivo

Molecular Cancer Therapeutics

Volumn 6, Issue 2, 2007, Pages 742-751

  Rajecki, Maria ^a,b   Kanerva, Anna ^a,b   Stenman, Ulf Håkan ^b   Tenhunen, Mikko ^b   Kangasniemi, Lotta ^a,b   Särkioja, Merja ^a,b   Ala Opas, Martti Y ^b   Alfthan, Henrik ^b   Sankila, Anna ^b   Rintala, Erkki ^b   Desmond, Renee A ^c   Hakkarainen, Tanja ^a,b   Hemminki, Akseli ^a,b  

^a UNIVERSITY OF HELSINKI   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHORIONIC GONADOTROPIN BETA SUBUNIT; CONDITIONALLY REPLICATING ADENOVIRUS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CANCER SURVIVAL; CONTROLLED STUDY; DRUG EFFICACY; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LUNG METASTASIS; MALE; MOUSE; NON INVASIVE MEASUREMENT; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; STATISTICAL SIGNIFICANCE; TRANSGENE; TUMOR CELL DESTRUCTION; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS REPLICATION;

ADENOVIRIDAE; ANIMALS; CELL SURVIVAL; CELLS, CULTURED; CHORIONIC GONADOTROPIN; DNA, VIRAL; GENE THERAPY; GENETIC VECTORS; HUMANS; KIDNEY; LUNG NEOPLASMS; MALE; MICE; MICE, NUDE; OLIGOPEPTIDES; ONCOLYTIC VIROTHERAPY; PROSTATIC NEOPLASMS; RECEPTORS, VIRUS; TUMOR CELLS, CULTURED; VIRUS REPLICATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 33847344280     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-06-0403     Document Type: Article

References (37)

1. Parkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000. The global picture. Eur J Cancer 2001;37:S4-66.
2. Cancer facts & figures 2005 [homepage on the internet]. US: American Cancer Society, Inc.; c2006 [cited July 12, 2006]. Available from: www.cancer.org/docroot/stt/stt_O.asp.
3. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999;281:1591-7.
4. Shelley M, Harrison C, Coles B, Wilt TJ, Mason MD. Chemotherapy for advanced prostate cancer (protocol). The Cochrane database of systematic reviews 2005; (1). Unique ID: DOI: 10.1002/14651858.CDO05247. Available from: http://www.mrw.interscience.wiley.com/cochrane/ cochrane_clsysrev_articles_protocols_fs.html.
5. Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. Nat Rev Cancer 2001;1:34-45.
6. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502-12.
7. Bauerschmitz GJ, Barker SD, Hemminki A. Adenoviral gene therapy for cancer: from vectors to targeted and replication competent agents. Int J Oncol 2002;21:1161-74.
8. Kanerva A, Hemminki A. Adenoviruses for treatment of cancer. Ann Med 2005;37:33-43.
9. Saukkonen K, Hemminki A. Tissue-specific promoters for cancer gene therapy. Expert Opin Biol Ther 2004;4:683-96.
10. Fueyo J, Gomez-Manzano C, Alemany R, et al. A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene 2000;19:2-12.
11. Heise C, Hermiston T, Johnson L, et al. An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy. Nat Med 2000;6:1134-9.
12. Russell WC. Update on adenovirus and its vectors. J Gen Virol 2000; 81:2573-604.
13. Sherr CJ. Cancer cell cycles. Science 1996;274:1672-7.
14. Phillips SM, Morton DG, Lee SJ, Wallace DM, Neoptolemos JP. Loss of heterozygosity of the retinoblastoma and adenomatous polyposis susceptibility gene loci and in chromosomes 10p, 10q and 16q in human prostate cancer. Br J Urol 1994;73:390-5.
15. Brooks JD, Bova GS, Isaacs WB. Allelic loss of the retinoblastoma gene in primary human prostatic adenocarcinomas. Prostate 1995;26: 35-9.
16. Kanerva A, Mikheeva GV, Krasnykh V, et al. Targeting adenovirus to the serotype 3 receptor increases gene transfer efficiency to ovarian cancer cells. Clin Cancer Res 2002;8:275-80.
17. Douglas JT, Kim M, Sumerel LA, Carey DE, Curial DT. Efficient oncolysis by a replicating adenovirus (ad) in vivo is critically dependent on tumor expression of primary ad receptors. Cancer Res 2001;61: 813-7.
18. Hemminki A, Dmitriev I, Liu B, Desmond RA, Alemany R, Curiel DT. Targeting oncolytic adenoviral agents to the epidermal growth factor pathway with a secretory fusion molecule. Cancer Res 2001;61: 6377-81.
19. Stevenson SC, Rollence M, White B, Weaver L, McClelland A. Human adenovirus serotypes 3 and 5 bind to two different cellular receptors via the fiber head domain. J Virol 1995;69:2850-7.
20. Segerman A, Atkinson JP, Marttila M, Dennerquist V, Wadell G, Arnberg N. Adenovirus type 11 uses CD46 as a cellular receptor. J Virol 2003;77:9183-91.
21. Pandha HS, Stockwin LH, Eaton J, et al. Coxsackie B and adenovirus receptor, integrin and major histocompatibility complex class I expression in human prostate cancer cell lines: implications for gene therapy strategies. Prostate Cancer Prostatic Dis 2003;6:6-11.
22. Okegawa T, Li Y, Pong RC, Bergelson JM, Zhou J, Hsieh JT. The dual impact of coxsackie and adenovirus receptor expression on human prostate cancer gene therapy. Cancer Res 2000;60: 5031-6.
23. Rauen KA, Sudilovsky D, Le JL, et al. Expression of the coxsackie adenovirus receptor in normal prostate and in primary and metastatic prostate carcinoma: potential relevance to gene therapy. Cancer Res 2002;62:3812-8.
24. Pang KW, Facteau S, Wegman T, O'Kane D, Russell SJ. Non-invasive in vivo monitoring of trackable viruses expressing soluble marker peptides. Nat Med 2002;8:527-31.
25. Phuong LK, Allen C, Pang KW, et al. Use of a vaccine strain of measles virus genetically engineered to produce carcinoembryonic antigen as a novel therapeutic agent against glioblastorna multiforme. Cancer Res 2003;63:2462-9.
26. Kanerva A, Zinn KR, Pang KW, et al. Noninvasive dual modality in vivo monitoring of the persistence and potency of a tumor targeted conditionally replicating adenovirus. Gene Ther 2005;12:87-94.
27. Hawkins LK, Johnson L, Bauzon M, et al. Gene delivery from the E3 region of replicating human adenovirus: Evaluation of the 6.7 K/gp19 K region. Gene Ther 2001;8:1123-31.
28. Alfthan H, Haglund C, Dabek J, Stenman UH. Concentrations of human choriogonadotropin, its β-subunit, and the core fragment of the β-subunit in serum and urine of men and nonpregnant women. Clin Chem 1992;38:1981-7.
29. Kanerva A, Zinn KR, Chaudhuri TR, et al. Enhanced therapeutic efficacy for ovarian cancer with a serotype 3 receptor-targeted oncolytic adenovirus. Mol Ther 2003;8:449-58.
30. Wenstrom KID, Owen J, Boots LR, DuBard MB. Elevated second-trimester human chorionic gonadotropin levels in association with poor pregnancy outcome. Am J Obstet Gynecol 1994;171:1038-41.
31. Stenman UH, Alfthan H, Hotakainen K. Human chorionic gonadotropin in cancer. Clin Biochem 2004;37:549-61.
32. Norman RJ, Menabawey M, Lowings C, Buck RH, Chard T. Relationship between blood and urine concentrations of intact human chorionic gonadotropin and its free subunits in early pregnancy. Obstet Gynecol 1987;69:590-3.
33. Shah VM, Newman J, Crocker J, Antonalkopoulos GN, Chapple CR, Collard MJ. Production of β-human chorionic gonadotropin by prostatic adenocarcinoma and transitional cell carcinoma of the upper urinary tract. Br J Exp Pathol 1987;68:871-8.
34. Kanerva A, Wang M, Bauerschmitz GJ, et al. Gene transfer to ovarian cancer versus normal tissues with fiber-modified adenoviruses. Mol Ther 2002;5:695-704.
35. Krasnykh V, Belousova N, Korokhov N, Mikheeva G, Curiel DT. Genetic targeting of an adenovirus vector via replacement of the fiber protein with the phage T4 fibritin. J Virol 2001;75:4176-83.
36. Dmitriev I, Krasnykh V, Miller CR, et al. An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism. J Virol 1998;72:9706-13.
37. Suzuki K, Fueyo J, Krasnykh V, Reynolds PN, Curiel DT, Alemany R. A conditionally replicative adenovirus with enhanced infectivity shows improved oncolytic potency. Clin Cancer Res 2001;7:120-6.